Home > Neurology > AAN 2022 > Parkinson’s Disease > IPX203 versus immediate release carbidopa-levodopa

IPX203 versus immediate release carbidopa-levodopa

Presented By
Prof. Robert Hauser, USF Parkinson's Disease and Movement Disorders Center, FL, USA
Conference
AAN 2022
Trial
Phase 3, RISE-PD
Doi
https://doi.org/10.55788/c441edbd
The RISE-PD study compared the safety and efficacy of IPX203 with immediate release carbidopa-levodopa (CD-LD) in Parkinson’s disease (PD) patients with motor fluctuations. IPX203, an investigational oral extended-release (ER) formulation of CD-LD, resulted in statistically significant improvement in “good on” time versus immediate release CD-LD, while requiring fewer daily dosages. IPX203 was specifically designed to provide rapid levodopa absorption to quickly reach the desired plasma concentration and to maintain levodopa concentrations within the therapeutic range for a longer period of time than immediate release CD-LD, and with less peak-to-trough fluctuation. Prof. Robert Hauser (USF Parkinson's Disease and Movement Disorders Center, FL, USA) explained that the phase 3 RISE-PD study (NCT03670953) was meant to test the efficacy and safety of IPX203 ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on